Manchester, United Kingdom

Kate Mary Smith

USPTO Granted Patents = 4 


 

Average Co-Inventor Count = 8.0

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2019-2024

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Kate Mary Smith

Introduction

Kate Mary Smith is a prominent inventor based in Manchester, GB. She has made significant strides in the field of biotechnology, particularly in the development of compounds that target specific enzyme activities. With a total of 4 patents to her name, her work is paving the way for advancements in medical treatments.

Latest Patents

Among her latest patents are the PARG inhibitory compounds. These compounds are designed to inhibit the activity of the PARG (Poly ADP-ribose glycohydrolase) enzyme. The invention details compounds of formula I, which are crucial in the treatment of proliferative disorders, including cancer. The patent also encompasses processes for preparing these compounds, pharmaceutical compositions that include them, and their applications in treating diseases where PARG activity plays a significant role.

Career Highlights

Kate Mary Smith is currently associated with Cancer Research Technology Limited, where she continues to innovate and contribute to cancer research. Her work is instrumental in developing new therapeutic strategies that could potentially improve patient outcomes.

Collaborations

Some of her notable coworkers include Alison E McGonagle and Allan Michael Jordan. Their collaborative efforts enhance the research environment and foster innovation in their projects.

Conclusion

Kate Mary Smith's contributions to the field of biotechnology and her innovative patents are vital in the ongoing fight against cancer and other proliferative disorders. Her work exemplifies the impact of dedicated research and collaboration in advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…